Preventing Cancer Metastases : Spaser Used to Destroy Tumor Cells
Synopsis: Spaser can be used as optical probe and when released into the body, find circulating tumor cells, stick to them and destroy these cells by breaking them apart to prevent cancer metastases.1
Author: Georgia State University2 Contact: gsu.edu
Published: 2017-08-21 Updated: 2020-02-06
The spaser absorbs laser light, heats up, causes shock waves in the cell and destroys the cell membrane.
Metastatic cancer occurs when cancer spreads to distant parts of the body, often to the bone, liver, lungs and brain, through a process called metastasis.
A nanolaser known as the spaser can serve as a super-bright, water-soluble, biocompatible probe capable of finding metastasized cancer cells in the blood stream and then killing these cells, according to a new research study.
The word spaser is an acronym for "Surface Plasmon Amplification by Stimulated Emission of Radiation". A spaser or plasmonic laser is a type of laser which aims to confine light at a subwavelength scale far below Rayleigh's diffraction limit of light. Spasers could find a wide range of applications, including fabrication of ultra-fast photonic nano circuits, microscopy, nanoscale lithography, and single-molecule biochemical sensing.
The study found the spaser can be used as an optical probe and when released into the body (possibly through an injection or drinking a solution), it can find and go after circulating tumor cells (CTCs), stick to them and destroy these cells by breaking them apart to prevent cancer metastases. The spaser absorbs laser light, heats up, causes shock waves in the cell and destroys the cell membrane. The findings are published in the journal Nature Communications.
The spaser is a nanoparticle, about 20 nanometers in size or hundreds times smaller than human cells. It has folic acid attached to its surface, which allows selective molecular targeting of cancer cells. The folate receptor is commonly overexpressed on the surface of most human cancer cells and is weakly expressed in normal cells.
The discovery was made by researchers at Georgia State University, the University of Arkansas for Medical Sciences, the University of Arkansas at Little Rock and the Siberian Branch of the Russian Academy of Science.
"There is no other method to reliably detect and destroy CTCs," said Dr. Mark Stockman, director of the Center for Nano-Optics and professor of physics at Georgia State.
"This is the first. This biocompatible spaser can go after these cells and destroy them without killing or damaging healthy cells. Any other chemistry would damage and likely kill healthy cells. Our findings could play a pivotal role in providing a better, life-saving treatment option for cancer patients."
Metastatic cancer occurs when cancer spreads to distant parts of the body, often to the bone, liver, lungs and brain, through a process called metastasis. Many types of cancers refer to this as stage IV cancer.
Once cancer spreads, it can be difficult to control, and most metastatic cancer can't be cured with current treatments, according to the National Institute of Health's National Cancer Institute. One of the most dangerous ways metastasizing occurs is through the CTCs, which this study aims to detect and destroy using spasers.
The spasers used in this study measure just 22 nanometers, setting the record for the smallest nanolasers. A nanometer is one-billionth of a meter. Most results were obtained with a gold, spherical nanoparticle surrounded by a silica shell and covered with a uranine dye, which is widely used for tracing and biomedical diagnostics.
The researchers studied the spaser's capabilities in vitro in human breast cancer cells with high folate receptor expression and endothelial cells with low folate receptor expression, as well as in mouse cells in vivo.
They found cells with spasers demonstrated high image contrasts with one or many individual "hot spots" at different laser energies above the spasing threshold. The presence of spasers was confirmed with several optical and electron microscopy techniques, which revealed an initial accumulation of individual spasers on the cell membrane followed by their entrance into the cell cytoplasm.
The study also found low toxicity of the spasers for human cells. At the same time, the spasers subjected to laser irradiation selectively killed the tumor cells without damaging the healthy ones.
Based on the study's results, spaser-based therapeutic applications with high-contrast imaging is a promising field. The data suggest spasers have high potential as therapeutic and diagnostic agents that integrate optical diagnosis and photothermal-based cell killing, using just a few laser pulses to kill cancer cells.
The study is funded by the National Institutes of Health, the National Science Foundation, the University of Arkansas for Medical Sciences and the U.S. Office of Naval Research. To read the paper, visit https://www.nature.com/articles/ncomms15528
2Source/Reference: Georgia State University (gsu.edu). Disabled World makes no warranties or representations in connection therewith. Content may have been edited for style, clarity or length.
Related Nanomedicine Documents
Full List of Nanomedicine Publications Full List of Disabled World News Updates
Recent Disability News and Updates
Full List of Disabled World News Updates
Disclaimer: Disabled World is strictly a news and information website provided for general informational purpose only and does not constitute medical advice. Materials presented are in no way meant to be a substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Please report outdated or inaccurate information to us.
Disclosure: Disabled World is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com. Any 3rd party offering or advertising on disabled-world.com does not constitute endorsement by Disabled World. View our Advertising Policy for further information.